PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today announced that is has filed a Current Report on Form 8-K with the Securities Exchange Commission describing the terms of the employment agreement with Ralph Makar, the Company’s newly appointed President and Chief Executive Officer.
